|
Q3 FY2026
As of Sep 30, 2026
|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||||||||||
| CURRENT ASSETS | |||||||||||||||||||
| Cash and cash equivalents | |||||||||||||||||||
| Other current assets | |||||||||||||||||||
| TOTAL CURRENT ASSETS | |||||||||||||||||||
| TOTAL ASSETS | |||||||||||||||||||
| Liabilities and Shareholders' Equity | |||||||||||||||||||
| CURRENT LIABILITIES | |||||||||||||||||||
| Accounts payable | |||||||||||||||||||
| Payable offering costs | |||||||||||||||||||
| Deferred fundraising receipts | |||||||||||||||||||
| Accrued liabilities | |||||||||||||||||||
| Employee compensation and benefits | |||||||||||||||||||
| TOTAL CURRENT LIABILITIES | |||||||||||||||||||
| TOTAL LIABILITIES | |||||||||||||||||||
| SHAREHOLDERS' EQUITY, see Note 4 | |||||||||||||||||||
| Additional paid in capital | |||||||||||||||||||
| Accumulated deficit | |||||||||||||||||||
| TOTAL SHAREHOLDERS' EQUITY | |||||||||||||||||||
| TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY |
Loading...